Christopher Kenney, MD, is a board-certified neurologist who spent the last 15 years caring for Parkinson’s disease patients and conducting clinical research in order to improve treatment options for those suffering from a variety of movement disorders.

Dr. Kenney’s core medical and neurology training took place at Boston University School of Medicine and at University of California, San Diego (UCSD), followed by a combined clinical and research fellowship at Baylor College of Medicine. Faculty positions were held at UCSD, Baylor and, most recently, Boston University. He has published over 50 manuscripts, abstracts and book chapters focused on Parkinson’s disease, hyperkinetic movement disorders, essential tremor and deep brain stimulation.

A transition from academia to the pharmaceutical industry seven years ago brought Dr. Kenney to three positions within clinical development. The first involved working at Merck Serono as a medical director with the objective of completing the Phase III development of safinamide for Parkinson’s disease. The next position was as a clinical indication leader overseeing the Phase II development of AFQ056/mavoglurant for Parkinson’s disease levodopa-induced dyskinesia. His current position is vice president of clinical development at Biotie Therapies, Inc. He is responsible for bringing tozadenant, an adenosine A2a antagonist, through Phase III for Parkinson’s disease.